In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Biotech Emerges as Late-Stage Licensee

Executive Summary

The sheer size of today's Big Pharmas has created a problem when it comes to licensing late-stage products; many of those available simply don't have large enough revenue projections to significantly contribute to the Big Pharmas' earnings. But larger biotechs, which don't necessarily need blockbusters to grow earnings, seem to have begun to fill the gap.

You may also be interested in...

Late-Stage Biotech In-Licensing

Are biotechs abandoning drug discovery-based business models in favor of in-licensing-based development and marketing strategies? In both annual count and, more dramatically, dollar volume, deals in which biotechs in-license late-stage products-from other biotechs, or from larger pharmaceutical companies-have spiked over the past two years.

Merck’s Molnupiravir Open License With Medicines Patent Pool May Be Model

Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts